(VIANEWS) - Moderna (MRNA), Mimecast Limited (MIME), Identiv (INVE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Moderna (MRNA)
1202.8% sales growth and 72.43% return on equity
Moderna's sales growth this year is expected to be 2434.2% and a negative 2.5% for next year.
Year-on-year quarterly revenue growth grew by 6398.5%, now sitting on 7.02B for the twelve trailing months.
Volume
Today's last reported volume for Moderna is 2226570 which is 74% below its average volume of 8566220.
Moderna's sales growth for the next quarter is 1202.8%. The company's growth estimates for the ongoing quarter and the next is 1694.9% and 1681.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 72.43%.
Volatility
Moderna's last day, last week, and last month's current intraday variation average was 3.27%, 3.92%, and 4.25%, respectively.
Moderna's highest amplitude of average volatility was 8.64% (day), 7.09% (last week), and 6.92% (last month), respectively.
Moderna's Stock Yearly Top and Bottom Value
Moderna's stock is valued at $175.56 at 11:22 EST, way under its 52-week high of $497.49 and way higher than its 52-week low of $102.66.
Moderna's Moving Average
Moderna's worth is way below its 50-day moving average of $298.96 and way below its 200-day moving average of $267.83.Previous days news about Moderna(MRNA)
- According to Bloomberg Quint on Tuesday, 29 March, "U.S. regulators cleared second booster doses of Covid-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.", "Based on an analysis of emerging data, a second booster dose of either the Pfizer-BioNTech or Moderna Covid-19 vaccine could help increase protection levels for these higher-risk individuals."
- Moderna’s covid booster shot will be offered to South African health workers . According to Bloomberg Quint on Monday, 28 March, "Sherpa, which is being run by Moderna and the SAMRC, is the second vaccine trial that Moderna will undertake in South Africa. ", "The aim of the study, which will target participants in the earlier Sisonke trial, is to compare how well the Moderna shot works in comparison to Pfizer Inc.'s shot as a boost, Gray said in an interview on Monday. "
- Pfizer, Moderna and j&j face shareholder pressure to broaden vaccine access. According to The Wall Street Journal on Sunday, 27 March, "Socially conscious investors and global-health activists are turning to shareholders to press Covid-19 vaccine manufacturers Pfizer Inc., Moderna Inc. and Johnson & Johnson to make more of their shots available to people in poorer countries."
- This coal company's 1-year return handily beats Moderna, Catalyst Pharmaceuticals, globalstar and dogecoin. According to Benzinga on Saturday, 26 March, "Since March 2021, Alpha Metallurgical stock's 1-year return has outperformed several of the world's most popular pharmaceutical, telecommunications stocks and cryptocurrencies: Moderna Inc (NASDAQ:MRNA), Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), Globalstar, Inc. (NASDAQ:GSAT) and Dogecoin (CRYPTO: DOGE)."
2. Mimecast Limited (MIME)
14.1% sales growth and 11.73% return on equity
Mimecast Limited offers cloud security and risk management for email and corporate data.
Mimecast Limited's sales growth this year is expected to be 18.2% and 14.8% for next year.
Year-on-year quarterly revenue growth grew by 20%, now sitting on 553.31M for the twelve trailing months.
Volume
Today's last reported volume for Mimecast Limited is 993093 which is 47.53% below its average volume of 1892930.
Mimecast Limited's sales growth is a negative 0% for the present quarter and 14.1% for the next. The company's growth estimates for the present quarter and the next is 6.1% and 10.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.73%.
Volatility
Mimecast Limited's last day, last week, and last month's current intraday variation average was 0.05%, 0.25%, and 0.15%, respectively.
Mimecast Limited's highest amplitude of average volatility was 0.19% (day), 0.49% (last week), and 0.36% (last month), respectively.
Mimecast Limited's Stock Yearly Top and Bottom Value
Mimecast Limited's stock is valued at $79.33 at 11:22 EST, below its 52-week high of $85.48 and way above its 52-week low of $38.84.
Mimecast Limited's Moving Average
Mimecast Limited's value is under its 50-day moving average of $79.53 and way higher than its 200-day moving average of $70.20.3. Identiv (INVE)
11.9% sales growth and 5.16% return on equity
Identiv, Inc. is a security company. It protects data, physical locations, and other things around the world.
Identiv's sales growth this year is anticipated to be 18.6% and 21.7% for next year.
Year-on-year quarterly revenue growth grew by 17%, now sitting on 100.09M for the twelve trailing months.
Volume
Today's last reported volume for Identiv is 23206 which is 88.53% below its average volume of 202321.
Identiv's sales growth for the next quarter is 11.9%. The company's growth estimates for the current quarter and the next is 400% and 180%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.16%.
Volatility
Identiv's last day, last week, and last month's current intraday variation average was 2.40%, 2.24%, and 3.26%, respectively.
Identiv's highest amplitude of average volatility was 7.19% (day), 5.16% (last week), and 5.52% (last month), respectively.
Identiv's Stock Yearly Top and Bottom Value
Identiv's stock is valued at $16.57 at 11:22 EST, way under its 52-week high of $25.25 and way higher than its 52-week low of $6.82.
Identiv's Moving Average
Identiv's worth is way below its 50-day moving average of $21.21 and under its 200-day moving average of $16.96.4. Community Bank System (CBU)
6.8% sales growth and 9.02% return on equity
Community Bank System, Inc. is the bank holding firm for Community Bank, N.A. it provides various financial and banking services for retail, commercial and municipal customers.
Community Bank System's sales growth this year is anticipated to be 6.1% and 5.3% for next year.
Year-on-year quarterly revenue growth grew by 2.7%, now sitting on 629.49M for the twelve trailing months.
Volume
Today's last reported volume for Community Bank System is 114228 which is 46.9% below its average volume of 215119.
Community Bank System's sales growth for the next quarter is 6.8%. The company's growth estimates for the ongoing quarter and the next is a negative 20.6% and negative -15.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.02%.
Volatility
Community Bank System's last day, last week, and last month's current intraday variation average was 1.51%, 1.12%, and 1.21%, respectively.
Community Bank System's highest amplitude of average volatility was 1.77% (day), 1.99% (last week), and 2.47% (last month), respectively.
Community Bank System's Stock Yearly Top and Bottom Value
Community Bank System's stock is valued at $71.04 at 11:22 EST, way below its 52-week high of $82.10 and higher than its 52-week low of $65.00.